Supernus Pharmaceuticals, Inc. $SUPN Stock Position Cut by PDT Partners LLC

Key Points

• PDT Partners LLC has reduced its stake in Supernus Pharmaceuticals by 32.0%, now owning approximately 0.07% of the company valued at $1.22 million.
• Analysts are optimistic, with Piper Sandler raising the target price from $36.00 to $40.00, and a consensus rating of "Moderate Buy" with an average price target of $43.00.
• Insider activity included significant sales, with SVP Frank Mottola selling 14,000 shares for approximately $623,140, and insiders selling a total of 179,606 shares worth $7.62 million last quarter.

PDT Partners LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 32.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,381 shares of the specialty pharmaceutical company's stock after selling 17,627 shares during the period. PDT Partners LLC owned approximately 0.07% of Supernus Pharmaceuticals worth $1,224,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals during the 1st quarter valued at $30,000. Versant Capital Management Inc boosted its stake in Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $42,000.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Piper Sandler raised their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ:SUPN opened at $44.93 on Thursday. The company's fifty day moving average is $37.43 and its two-hundred day moving average is $34.06. The company has a market cap of $2.52 billion, a P/E ratio of 39.07 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.94.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at $689,726.96. This represents a 47.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 179,606 shares of company stock worth $7,617,005. Company insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.